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specific destruction of mutant mtDNA.
In combination with adeno-associated
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of incurable mtDNA disorders using
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(P.A. Gammage).Mitochondrial Genetics and Human Disease
In the past 30 years the medical relevance of mtDNA (see Glossary) has brought this unusual
genome to the fore [1]. This is, in the most part, owing to the increasing recognition of mitochon-
dria as a major biochemical hub, the confirmation of mitochondrial dysfunction and mtDNA
mutations in common diseases [1,2], and the role of mtDNA in disease-relevant cell signalling
pathways [3,4], in concert with a number of high-profile attempts at preventing untreatable,
hereditary mitochondrial disease using in vitro fertilisation techniques [known as mitochondrial
replacement therapy or mitochondrial donation] [5]. With such an upsurge of interest in
mtDNA, effort towards generating methods for robust manipulation of mtDNA, for both clinical
and experimental means, has been galvanised [6,7].
Mitochondrial diseases are one of the most common forms of inherited metabolic disease, with
asymptomatic carriers of pathogenicmtDNA variants estimated at one in 200 adults, and approx-
imately one in 5000 adults affected by resultant mitochondrial disease [8]. The presentation of pa-
tients bearing identical mtDNA mutations is often highly variable, with mostly unpredictable
penetrance and severity. When combined with the current lack of reliable biomarkers of mito-
chondrial disease, diagnosis of these conditions is a major challenge [4].
Despite being clinically and genetically described for several decades, there are still no curative
therapeutics for patients with mtDNA disease. As a branch of medicine still lacking such
treatment, the clinical potential of gene therapy for mitochondrial disease is considerable [1].
Fundamentals of Human Mitochondrial Genetics and Heteroplasmy
Manipulation
Human mtDNA is a small, multicopy genome encoding 13 protein subunits of the respiratory
chain complexes I, III, and IV and ATP synthase, and all RNA molecules necessary for their trans-
lation by mitochondrial ribosomes [9]. As with any genetic material, mtDNA is susceptible to the
introduction of point mutations and rearrangements by a combination of endogenous andTrends in Molecular Medicine, Month 2020, Vol. xx, No. xx https://doi.org/10.1016/j.molmed.2020.02.006 1
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Glossary
Adeno-associated virus (AAV): non‐
enveloped, non‐integrating virus used to
deliver DNA to target cell or tissue.
Clustered regularly interspaced
short palindromic repeats
(CRISPR)/CRISPR-associated
protein 9 (Cas9): Cas is guided by
short RNA sequences – CRISPR – to
specific DNA regions, which evolved as
a specific prokaryotic defence strategy
against phage infection. In contrast to
ZFNs and TALENs, the Cas9 enzyme
needs guide RNAs to target any given
DNA sequence.
Cybrid: cybrid cells are generated by
the fusion of a cytoplast (enucleated cell)
derived from patients bearing mtDNA
mutations with an immortalised cell
lackingmtDNA (commonly referred to as
ρ0). Through this process, cell lines with
varying mutation heteroplasmy on
similar nuclear genetic backgrounds can
Trends in Molecular Medicineexogenous factors, and these genetic lesions are observed in human mitochondrial disease
[8,10]. However, as mtDNA is multicopy, mutated genomes can coexist with wild-type genomes,
a state termed heteroplasmy (Figure 1A).
For the impact of heteroplasmic mtDNA mutations to biochemically and clinically manifest,
the ratio of mutated to nonmutated mtDNA has to exceed a certain upper limit, a phenom-
enon known as the threshold effect (Figure 1B) [10]. This effect is mutation specific, with
large deletions of mtDNA that encompass several genes generally manifesting at lower
heteroplasmic levels (~60%) than single point mutations. These thresholds also vary be-
tween individuals with the same mutation as well as between tissues in a single patient
(Figure 1A,B).
While there is general agreement on the maternal inheritance of human mtDNA, the exact mech-
anisms of the inheritance and segregation of mtDNA, from tissues to populations, remain a matter
of debate. A genetic bottleneck during female gamete development has been identified as
the major source of variance between generations, often resulting in unaffected mothers bearing
children with severe mitochondrial disease (Figure 1A) [11]. Further complexity is added through
mutation-specific variance, where the samemutation can be of variable distribution and pathoge-
nicity within an individual as well as between individuals [10].be created.
Double-strand break (DSB): through
the activity of restriction endonucleases,
DSBs are induced. In mitochondria, this
results in the rapid degradation of linear
mtDNA molecules.
Heteroplasmy: the co-occurrence
of mtDNA molecules of different
sequences in the same cell, whether
natural polymorphisms or
mutations.
Mitochondrial DNA (mtDNA): a
circular 16.5-kb molecule encoding
37 genes (two rRNAs, 22 tRNAs, and
11 mRNAs) in Mammalia.
Mitochondrial replacement therapy:
an approach to the prevention of
mitochondrial disease inheritance by
swapping mitochondria with mutated
mtDNA molecules with healthy
mtDNA-containing mitochondria in
oocytes.
mtDNA copy number: the number of
mtDNA molecules per cell.
Repeat variable diresidue (RVD): the
two amino acid positions in each
repeating TALE DNA-binding module
that determine the binding specificity of
that 33–35-aa module.
Threshold effect: a term used to
describe the extent of mtDNA mutation
burden that must be exceeded for a
biochemical or clinical phenotype to
manifest.
Transcription activator-like effector
nucleases (TALENs): a TALE DNA-
binding domain fused to a DNA cleavage
domain, engineered to target specific
DNA sequences.
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Figure 1. Heredity of Mitochondrial DNA (mtDNA) Heteroplasmy and Clinical Mosaicism. (A) mtDNA
heteroplasmy, a state in which wild-type (green circle) and mutant (yellow circle) mtDNA molecules coexist in a certain
proportion with one another, is initially determined in primordial germ cells in the maternal lineage during embryogenesis
indicated by ‘genetic bottleneck’. Once fertilised, the mutation load of the F1 generation can be unevenly distributed
throughout the developing embryo, leading to mosaicism within and between the tissues of an individual. Mutations can
also have tissue-specific impacts, leading to a complex clinical picture. (B) An example of within-tissue mosaicism of a
single mutation of mtDNA from patient skeletal muscle. A cross-section stained for cytochrome c oxidase (COX) (brown
and succinate dehydrogenase (SDH) (blue) activity. This assessment indicates the contributions of the mitochondrial and
nuclear genomes to mitochondrial dysfunction, as COX requires mtDNA-encoded subunits whereas SDH does not. When
separate regions of such a tissue preparation are analysed (1, 2), the degree of COX deficiency is proportional to the
mutation heteroplasmy.
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Zinc-finger nuclease (ZFN): a zinc-
finger DNA-binding domain fused to a
DNA cleavage domain, engineered to
target specific DNA sequences.
Trends in Molecular MedicineWhile the stochastic transmission of mtDNA continues to be a major clinical complication, the
threshold effect has been the source of inspiration for numerous therapeutic strategies, aiming
to reduce the heteroplasmy of deleterious variants to alleviate disease through both direct and
indirect targeting of pathogenic mitochondrial genomes [12], an approach often referred to as
heteroplasmy shifting. This approach takes advantage of the multicopy nature of mtDNA and
the functionally recessive nature of virtually all pathogenic mutations in mtDNA [13]. As
heteroplasmic mtDNA mutations coexist with wild-type mtDNA, shifting mtDNA heteroplasmy
below the pathogenic threshold in somatic tissues offers a rational approach to the treatment
of primary mitochondrial disease [13] (Figure 2A).Trends in Molecular Medicine
Figure 2. Manipulating Mitochondrial DNA (mtDNA) Heteroplasmy with Engineered Mitochondrial Nucleases. (A) A schematic of therapeutic mtDNA
heteroplasmy manipulation based on in vitro observations. An initial heteroplasmic ratio with a corresponding mitochondrial defect is rapidly altered by treatment with
mitochondrially targeted nucleases specific to the mutation in question. A brief, temporary depletion of total mtDNA copy number may follow, with ensuing rounds of
DNA replication resulting in shifted mtDNA heteroplasmy away from the mutant, with concomitant improvements in mitochondrial function. (B) Mitochondrially targeted
nucleases currently used for heteroplasmy manipulation. mitoRE, mitochondrially targeted restriction endonuclease; mtZFN, mitochondrially targeted zinc-finger
nuclease; mitoTALEN, mitochondrially targeted transcription activator-like effector nuclease. All classes of nuclease are expressed in the cytoplasm and imported into
mitochondria via the TIM/TOM machinery (not depicted). Once within the mitochondrial matrix, the mutant haplotype is specifically bound. Proximal FokI domains
dimerise and introduce a double-strand break, which results in rapid turnover of the cleaved mtDNA by, possibly among others, the known mitochondrial exonuclease
activity of Pol γ and MGME1. (C) Putative mtZFN target site for m.8993TNG and the structure of zinc-finger protein (ZFP) (white) bound to a cognate DNA target (blue).
Green spheres indicate zinc atoms. Zoom panel exemplifies protein–DNA interaction (PDB 1P47 [67]). (D) Putative mitoTALEN target site for m.8993TNG and the
structure of TALE (white) bound to a cognate DNA target (blue). Zoom panel exemplifies protein–DNA interaction (PDB 3UGM [68]).
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upregulation of mitochondrial turnover [14,15]; the use of antisense oligonucleotides to block
mutant mtDNA replication [16]; xenotopic expression of DNA recombination enzymes [17]; the
use of mitochondrial toxins [18]; general toxins [19]; G-quadruplex-binding agents [20]; and the
application of programmable nucleases [21,22]. It is the lattermost of these approaches that
we discuss in detail (Figure 2B).
Experimental Origins of Direct Heteroplasmy Manipulation
The first reported heteroplasmy shifting approaches made use of peptide nucleic acid (PNA)
oligomers [16,23]. PNAs are synthetic polymers comprising canonical DNA bases linked in series
through a repeating N-(2-aminoethyl)-glycine backbone by peptide bonds. The absence of
negatively charged phosphates in PNA, compared with DNA, was seen as advantageous with
regard to mitochondrial import competence, as the electrochemical potential across the inner
mitochondrial membrane (IMM) sits at ~−180 mV, effectively precluding the import of DNA and
RNA molecules. Once within mitochondria, the binding of a PNA molecule to a specific mutant
mtDNA sequence, but not wild type, was predicted to preferentially block the replication of mutant
mtDNA, thereby shifting mtDNA heteroplasmy in a replication-dependent fashion. Initial work re-
ported encouraging results, with specific stalling of DNA replication through PNA binding to mutant
mtDNA templates in vitro [16]. However, later efforts that conjugated PNA oligomers to mitochondrial
targeting sequences (MTS) or positively charged triphenylphosphoniummoieties that facilitate themi-
tochondrial uptake of small molecules [23–25] failed to demonstrate mtDNA heteroplasmy shifts in
cultured cells. More recently, MTS-mediated delivery of PNA 4-mers to themitochondrial matrix of liv-
ing cells has been achieved [26]. However, PNAs of at least 7-mer length would be required for a
unique site in mtDNA to be targeted, and whether single-stranded mtDNA at the replication
fork is readily bound by PNA remains to be determined. A similar approach has also emerged
attempting to achieve mtDNA mutation-specific antireplicative effects using imported RNA
molecules [27]. However, in addition to the question of single-stranded mtDNA accessibility
at the replication fork, the import of RNA into mammalian mitochondria is contentious, with
strong evidence against the existence of any efficiently operating pathway [7].
The earliest experiments in the field of nuclease-mediated heteroplasmy shifting used
mitochondrially targeted restriction endonucleases (mitoREs), highly specific bacterial endonucle-
ases that target and cleave specific foreign sequences in the ‘innate immunity’ restriction-
modification system of bacteria [28]. This approach was first explored using a mitochondrially
targeted form of the restriction endonuclease PstI, which was capable of depleting mtDNA
copy number when expressed in mouse cells containing mtDNA with a PstI recognition site
[28]. Heteroplasmy shifting activity was also demonstrated when a hybrid cell line containing
both rat mtDNA (bearing two PstI sites) and an alternative mouse mtDNA (without any PstI
sites) was transfected with the same mitoPstI construct, resulting in a specific shift towards the
mouse haplotype [28]. In later work, a mitochondrially targeted form of SmaI was used in
patient-derived cybrid cells, exploiting a unique SmaI recognition site introduced by the
pathogenic mtDNA variant m.8993TNG, associated with neuropathy, ataxia, retinitis pigmentosa
(NARP) syndrome. This resulted in complete elimination of the m.8993TNG allele within 48 h, ac-
companied by improvement in measures of mitochondrial physiology [29,30].
Besides an unidentified form of copy number control, which both maintains stable cellular mtDNA
copy number over time and ensures the recovery of copy number following nucleolytic cleavage of
mutant mtDNAs [31], the precise mechanism underlying heteroplasmy shifts in these experiments
was unclear. Initially, a lack of DNA repair in mitochondria was the speculated mechanism underpin-
ning heteroplasmic shifts after the introduction of DNA double-strand breaks (DSBs) [31].4 Trends in Molecular Medicine, Month 2020, Vol. xx, No. xx
Trends in Molecular MedicineHowever, it has since been determined that, while not only lacking DSB repair, mammalianmitochon-
dria possess a highly efficient mechanism for degradation of linear DNA molecules involving the
exonucleolytic activity of the replicative mtDNA polymerase Pol γ, exonuclease MGME1 and the
DNA helicase Twinkle [32–34], underpinning the heteroplasmy-shifting capacity of DSBs in mtDNA.
Nevertheless, while the mechanism underlying heteroplasmy shifts remained unclear, these early
studies offered proof of principle for nuclease-mediated heteroplasmy shifting approaches, tempered
by the reality that m.8993TNG is one of very few pathogenic mutations known to introduce a unique
mitoRE site into mtDNA. Limited clinical application notwithstanding, mitoRE approaches developed
further [35–37], culminating in the demonstration of large heteroplasmic shifts of a nonpathogenic
mtDNA variant in the NZB/BALBc mouse model by means of the mitoRE ApaLI [36] and later across
multiple mouse tissues when delivered by adeno-associated virus (AAV) [38,39].
The use of mitoREs in heteroplasmy manipulation was the first significant step in nuclease-
mediated mammalian mitochondrial genome engineering. However, mitoRE approaches are
profoundly limited by the availability of REs for any given site produced by mtDNA mutations,
and the refractory nature of REs to the engineering of alternate DNA binding specificity rendered
this avenue unsuitable for further development.
Heteroplasmy Shifting in the Era of Programmable Mitochondrial Nucleases
With longstanding efforts in nuclear genome manipulation yielding zinc-finger protein (ZFP) and
transcription activator-like effector (TALE) technologies [40], early forms of both mitochondrially
targeted zinc-finger nucleases (mtZFNs) and mitochondrially targeted TALE nucleases
(mitoTALENs) were soon to follow [21,22,41]. The principle of both technologies lies in sequence
specific DNA-binding domains, delivered to mitochondria using MTS peptides, coupled to the
functionally dimeric, sequence nonspecific endonuclease domain from the RE FokI (Figure 2B).
This approach creates a DSB only when both monomers are bound to the target DNA, limiting
off-target activity as the nucleolytic reagent is assembled and active only at the target site [40].
For both mtZFNs and mitoTALENs, sequence specificity is conveyed via protein–DNA interac-
tions through tandemly linked repetitive modules, varying at key nucleic acid-contacting residues
that are derived from either eukaryotic (ZFP) or bacterial (TALE) DNA-binding proteins.
Two studies describing the use of clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR-associated protein 9 (Cas9) in mitochondria have been published in recent
years [42,43]. However, the major hurdle to this approach – RNA import of guide RNA-containing
molecules into mitochondria, an essential component of this programmable nuclease system – is
not adequately addressed by the authors and these reports are replete with unconvincing data [7].
Further, Cas9 endonucleases are subject to target site limitations in terms of the length of site that
may be efficiently targeted (typically ~15–22 bp) and the proscribed protospacer-adjacent motif
(PAM). PAM sites are 2–6 bp sequences that are essential for the introduction of a DSB into DNA,
varying between the Cas9 species used. The limitations in target site preference presented by even
the most permissive PAM-bearing Cas9 variants would render a mitochondrial CRISPR/Cas9 ap-
proach unable to target the majority of pathogenic mtDNA mutations. Therefore, even if an efficient
mitochondrial CRISPR/Cas9 platform were to be created, it would be of limited use in the context
of therapeutic heteroplasmy shifting (see Table 1 for a summary).
Development and In Vitro Use of mtZFN Technology
Zinc-finger nucleic acid-binding motifs are among the most abundant protein folds in eukaryotic biol-
ogy. The capacity for DNA sequence-specific binding of Cys2His2 ZFPs is mediated by repeating
~25-amino-acid (aa) ZFP modules, or fingers, that each bind a 3-bp sequence. This binding is coor-
dinated 5′–3′ in a C-terminal to N-terminal orientation through hydrogen bonding in the major groove,Trends in Molecular Medicine, Month 2020, Vol. xx, No. xx 5
Table 1. Comparison of Engineered Mitochondrial Nucleases
Feature mtZFN mitoTALEN CRISPR/Cas9
Motif ββα RVD Cas9/gRNA
Interaction Protein–DNA Protein–DNA RNA–DNA
Binding 1 ZFP:3 (+1) bp 1 TALE:1 bp 1 gRNA:18–22 bp
Specificity 1 bp 1 bp Unknown
Off target
mtDNA At high expression At high expression Unknown
Nuclear Not detected Unknown Unknown
AAV compatible Yes Two capsids needed Yes
Pros Small, highly specific,
several in-body clinical trials
Easy to design Easy to design
Cons Difficult to design Large, limited target sites Mitochondrial RNA import,
limited target sites
Trends in Molecular Medicinewith additional cross-strand contacts to the final nucleotide of the preceding triplet and nonspecific
phosphate interactions [44] (Figure 2B,C). These zinc-finger domains, originally characterised in the
murine transcription factor zif268, comprise antiparallel β-strands and a zinc ion-stabilised α-helix
formed through the invariant cysteine and histidine residues for which the fold is named, arranged
in a ββα configuration. DNA binding is conveyed by the α-helical residues 1, 2, 3, and 6 of the ZFP
[44] (Figure 2C), which when arranged in tandem using short flexible linkers, form an engineered,
sequence-specific DNA-binding ZFP. In the case of engineered ZFPs, typically four to six fingers
(12–18 bp target site) are used per monomer, providing a total binding site of 24–36 bp.
The rational construction of ZFPs from preselected libraries is challenging, as DNA binding of
consecutive fingers is highly DNA/ZFP context dependent. As such, substantial libraries of can-
didate ZFPs and linkers were created using phage display [44], which have been further iterated
to provide targeting depth that allows the generation of ZFPs to virtually any DNA sequence [45].
The potential of zinc-finger-based approaches to mtDNAmanipulation was first seen in the dem-
onstration of site-specific methylase activity by a three-finger, monomeric, mitochondrially
targeted ZFP specific to m.8993TNG, fused to DNA methyltransferase 3a [46]. The use of a
nuclear export signal (NES) was essential for mitochondrial localisation of ZFPs in these experi-
ments, as cryptic internal nuclear localisation signals form an intrinsic part of the ZFP motif. This
work was further built on with a rudimentary mtZFN design for heteroplasmy shifting, where
two FokI domains separated by a long, flexible linker are attached to a single ZFP monomer spe-
cific to m.8993TNG [41]. This early mtZFN design was capable of shifting heteroplasmy in cybrid
cells but was limited to a single ZFP binding site (four fingers, 12 bp) and was a constitutively ac-
tive nuclease, leading to undesired mtDNA copy number depletions that limited further use.
Early attempts at generating a dimeric mtZFN failed to produce efficacious reagents [41,47] until an
optimised architecture was designed capable of shifting m.8993TNG and ‘common deletion’
heteroplasmy in cybrid cells, demonstrating recovery of mitochondrial function in the latter [21].
While incorporating rational protein design alterations, these dimeric constructs also exploited an
engineered form of FokI bearing mutations in the protein–protein dimerisation interface required for
DSB induction [48,49]. These paired interface mutations in (+) and (−) versions of the endogenous
FokI C-terminal domain result in electrostatic repulsion between (+)/(+) and (−)/(−) domains, demon-
strating significantly diminished formation of homodimers and commensurate improvement of
heteroplasmy shifting coupled to decreased mtDNA copy number depletion.6 Trends in Molecular Medicine, Month 2020, Vol. xx, No. xx
Trends in Molecular MedicineLater studies have detailed the variation in heteroplasmy shifting efficiency seen with these chime-
ric enzymes based on the rate of catalysis and associated off-target activity, resulting in near-
complete elimination of mutant mtDNA with a single, transient treatment of mtZFNs when
expression levels are fine-tuned [50]. This approach was subsequently used as an experimental
tool to generate isogenic cell lines with variable mtDNA heteroplasmy, allowing assessment of
metabolic rewiring in the presence of mtDNA mutation-derived metabolic dysfunction [51].
Development and In Vitro Use of mitoTALENs
The TALE DNA-binding domains used in mitoTALENs are derived from Xanthomonas bacteria,
which deliver TALEs into plant cells via type III secretion mechanisms to activate host promoters
that enable infection and propagation [52]. The DNA sequence-specific binding of mitoTALENs is
mediated by 33–35-aa modules, formed of two α-helices linked by a loop, that each bind a 1-bp
site in the major groove through two hypervariable or repeat variable diresidues (RVDs)
contained in the loop region, with additional nonspecific phosphate interactions mediated by
the helices [52] (Figure 2B,D). The structural basis of TALE DNA-binding specificity, in stark com-
parison with ZFPs, is simple and mostly reproducible, with a minimal library of RVD modules
encoding all base specificities [40]. However, this simplicity is coupled to limitations in DNA target
site preference, in terms of sequence composition, length, and a strong preference for T in
position 0 at the 5′ end of the binding site [40,52] (Figure 2D).
The development of mitoTALENs was first reported with data describing the manipulation of ‘com-
mon deletion’ and m.14459GNA point mutation heteroplasmy in cybrid cells, with recovery of mito-
chondrial function observed in the latter [22]. Bacman and colleagues exploited the requirement for
T at position 0 in the TALE binding site, which is produced in the complementary H-strand by the
m.14459GNA mutation, resulting in a highly specific reagent to this site; an approach that is termed
the T0 strategy. However, two major challenges faced the further development of mitoTALENs:
first, achieving single-nucleotide binding specificity atmutation sites that are not NNAor NNT and can-
not be targeted using a T0 strategy, and second, creating specificmitoTALENswith unconventionally
short target sites that will be compatible with downstream gene therapy approaches such as AAV,
which cannot easily deliver the length of DNA-encoding sequence required for full-lengthmitoTALENs
as described in the original reports. AlthoughmitoTALEN activity at target sites that do not permit the
T0 strategy appears to be variable [22,53], some success was had in producing truncated TALE do-
mains to allow AAV compatibility, at the cost of diminished binding specificity [54].
mitoTALENs, or close variants thereof, have also been applied to: (i) manipulate the heteroplasmy
of induced pluripotent stem cells (iPSCs) bearing the m.3243ANG and m.13513GNA mutations
[55,56]; (ii) induce single-strand breaks in mtDNA [57]; and (iii) shift the heteroplasmy of oocytes
and oocyte–cytoplast fusions [53]. A further variant of TALE-based mitochondrial nuclease,
where TALE DNA-binding domains are fused to the linker and catalytic domain of the monomeric
homing endonuclease I-TevI from T4 phage, known as mitoTev-TALE, has also been reported
[58]. While this architecture appears capable of modest heteroplasmy shifting activity, inherent
specificities associated with the TevI nuclease domain and linker, in addition to the difficulties
associated with use of a constitutively active nuclease, are likely to limit further applications.
Manipulating mtDNA Heteroplasmy In Vivo
The transition from cell cultures to autochthonous animal models of disease biology is a challeng-
ing process for any gene therapy. Translation of potential gene therapies for heteroplasmic
mitochondrial disease are particularly vexed in this regard, as state-of-the-art methods for manip-
ulating mtDNA do not currently allow directed generation of disease models to test emerging
approaches. Presently, the only available model of pathogenic heteroplasmic mtDNA mutationTrends in Molecular Medicine, Month 2020, Vol. xx, No. xx 7
Trends in Molecular Medicineis the m.5024CNT mouse, generated through laborious random mutagenesis and extensive
breeding/screening. This animal bears a heteroplasmic mutation in the acceptor stem of mito-
chondrial tRNA alanine (mt-tRNAAla) and recapitulates molecular features of mitochondrial
disease, such as tRNA instability, diminished mitochondrial translation, and metabolic indications
of heart failure, at high levels of heteroplasmy [59]. As such, the m.5024CNT model has been es-
sential to proof-of-principle experiments for the in vivo manipulation of pathogenic mtDNA
heteroplasmy by mtZFNs and mitoTALENs.
While the target organ and delivery site are major determinants of the medium used to convey
therapeutic genetic cargo across gene therapies, the current gold-standard modality for somatic
gene therapy is AAV (Box 1).
Several serotypes of AAV demonstrate specificity for skeletal and heart muscle (e.g., AAV6, AAV9,
and engineered serotypes thereof) and despite limited DNA-packaging capacity, have remained
the vector of choice for in vivo experiments using mitochondrially targeted nucleases. The first
application of mtZFNs in vivo used the engineered AAV9-derived serotype AAV9.45, a liver-
detargeted form of the wild-type AAV9 that exhibits approximately tenfold-lower transduction in
the liver, a major off-target of the wild-type AAV [60]. By in vitro screening for heteroplasmy shifting
activity in m.5024CNT mouse embryonic fibroblasts (MEFs), a pair of mtZFNs specific to a 28 bp
binding site, including the m.5024CNT mutation, were selected. While the mtZFN-encoding se-
quences are, theoretically, of proportions amenable to packaging within a single AAV capsid (1.2–
1.4 kb per monomer), initial proof-of-concept experiments were performed using co-injected
AAVs, with the twomtZFNmonomers encoded in two separate AAV genomes. Using this approach,
efficient viral transduction of the heart was achieved, and large shifts of mtDNA heteroplasmy (from
~70% to ~35% m.5024CNT) were detected 10 weeks after intravenous administration of AAVs in
adult animals. These shifts were accompanied by commensurately increased steady-state levels of
mt-tRNAAla and, at optimised doses, improved mitochondrial metabolism in heart tissue with no de-
tectable depletions ofmtDNA copy number. Importantly, irrespective of dose employed, no evidence
of off-target effects in the nuclear genome were observed [61].
Proof of concept for the use of mitoTALENs in vivo utilised wild-type AAV9, also employing the co-
administration of two AAV genomes, each encoding onemitoTALENmonomer. Following screening
of mitoTALEN candidate pairs in MEFs, a pair of mitoTALENs specific to a 21-bp binding site, includ-
ing the m.5024CNT mutation, exploiting the previously mentioned T0 strategy were selected. Focal
injection of AAVs encoding these mitoTALENs into the tibialis anterior muscle led to variable shifts
in heteroplasmy that were stable over time and linked to an increased mt-tRNAAla steady-state
level in animals demonstrating large shifts from a high-mutant-load baseline at 24 weeks
post-injection [62]. Following systemic administration of AAV in neonates, modest shifts inBox 1. Adeno-Associated Viruses.
Naturally occurring AAVs of the Dependoparvovirus genus comprise a protein-only, unenveloped capsid formed of three
structural proteins and do not encode a full complement of replicative or expression-associated viral genes required for a
complete lytic cycle within their compact (~4.2 kb), single-stranded DNA genome [65]. Once within a given human cell, the
AAV genome begins the lysogenic cycle, integrating into the AAVS1 locus on chromosome 21 through an incompletely
understood mechanism mediated by inverted terminal repeats (ITRs). The replication and release of AAV capsids from
the cell, completing the lysogenic/lytic cycle, is dependent on polymerases, helicases, and other transcription-effecting
genes expressed by either adenovirus or herpesvirus. AAV infection is widespread among mammals and is not known
to cause disease or significant immunogenicity, with numerous serotypes of AAV demonstrating significant tropism for
individual tissues. Given their capacity to infect both mitotic and post-mitotic cells, to be maintained episomally, and the
broad range of highly tissue-specific serotypes available, AAVs have outstripped previous gene therapy vehicles, such
as adenoviruses or retroviruses, in all aspects but DNA packaging capacity.
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Clinician’s Corner
No curative therapies for mitochondrial
disorders are available and treatment
options are very limited. Typically,
symptoms arise when mutated mtDNA
molecules exceed a ~60% threshold,
where the remaining healthy fraction
can no longer compensate for the loss
of function. Direct correction of mtDNA
mutations (N300 known) in situ is not
possible due to technical and, as
is likely, biological reasons. The
development of engineered nucleases
targeted to mitochondria allows
cleavage of the mutant mtDNA in a
mixed or heteroplasmic, multicopy
population. Subsequently, owing to
robust mtDNA copy number control,
the remaining normal copies of mtDNA
replicate and repopulate treated
cells. This ‘shifting’ results in a
diminished proportion of mutated
mtDNA molecules, potentially to
subsymptomatic levels, which allows
recovery of mitochondrial function.
The design of these nucleases is
generally not limited by the sequence
targeted. However, to date, these
approaches have been exclusively
limited to DNA-interacting protein
modules such as mtZFNs and
mitoTALENs. Owing to issues with
targeting guide RNA to mitochondria
and limited targetable sites in mtDNA,
CRISPR/Cas9 is unlikely to present a
viable route to heteroplasmy shifting.
Combining tissue-specific AAVs with
these nucleases has been proven
to be effective in preclinical mouse
models of a mitochondrial tRNA
mutation that presents with cardiomy-
opathy. These first reports of in vivomi-
tochondrial gene therapy demonstrate
effective alteration of the mutation
load in affected tissues of adult ani-
mals, a major conceptual advance to-
wards gene therapy for heteroplasmic
mitochondrial disease.
Trends in Molecular Medicineheteroplasmy (≤15% change) were also detected in heart and quadriceps muscles. Shifts of
heteroplasmy by mitoTALENs were not associated with depletions of mtDNA copy number
or the generation of deleted mtDNAs, as had previously been reported in connection with
mitoREs; however, the effects of mitoTALENs on nuclear DNA were not assessed.
Clinical Outlook
At present, pre‐clinical data for mtZFN and mitoTALEN approaches appear encouraging.
Both platforms permit re-engineering to target multiple mtDNA mutations in vitro [21,22,53–56]
and can be successfully translated to induce broadly similar shifts of mutation heteroplasmy across
entire organs and muscle groups with rescue of molecular disease phenotypes in vivo [60,61].
However, the following challenges still face both approaches in the transition to clinical trials.
Immunogenicity
While the immunogenicity of AAV capsids is a broadly discussed issue of relevance to most gene
therapies [63], the immunogenicity of the encoded transgene is often overlooked. In the case of
engineered nucleases, an obvious source of potential immune activation is the FokI catalytic
domain derived from bacteria. It is likely that, through the turnover of mitochondria by autophagy,
peptides from the FokI domains of mitochondrial nucleases will be presented to T cells at the
plasma membrane. In the case of mitoTALENs, the same issue is of relevance with regard to
the TALE DNA-binding domain itself, which is of bacterial origin. Although it is currently unclear
whether peptides from the FokI or TALE domains will mediate an immune response, this is an
open question that remains to be addressed.
Off-Target Effects in Nuclear DNA and mtDNA
Assessing the safety of gene therapy is of paramount importance, and unexpected off-target
effects in the genome are an ongoing concern. However, given the mitochondrial localisation of
mtZFNs and mitoTALENs, these concerns are somewhat muted compared with nuclear DNA
gene editing. This is because any rare off-target events in mtDNA, due to poor reagent specificity
or nuclease overdose, do not result in the introduction of mutations into mtDNA but in the degra-
dation of the genome containing the erroneous DNA DSB [32–34]. Thus, in a worst-case scenario,
partial mtDNA copy number depletions could be observed. It is possible to attempt to circumvent
this issue by predicting the optimal nuclease dosage and heteroplasmy shift efficiencies using
mathematical modelling [64]. However, any pathological effect of such partial depletions remains
unclear, and in the context of newly engineered FokI domains, with up to 3000-fold-lower off-
target activity [65], the issues of nuclease dosage seen with earlier obligatory heterodimeric itera-
tions of this domain used in mitochondria [50] seem unlikely to present a problem.
Owing to the mitochondrial localisation of these nucleases, nuclear DNA off-targets are unlikely
to present an issue with the clinical translation of these technologies. While this possibility was
investigated for mtZFNs, with no off-target activity in nuclear DNA identified [61], the same has
not been demonstrated for mitoTALENs [62]. Nonetheless, further robust analysis of both the
nuclear and the mitochondrial off-target milieu will be needed to allow the transition of these
promising technologies from the laboratory to the clinic.
Reliable Generation of Specific Reagents
Both mtZFNs and mitoTALENs have shown activity at multiple mtDNA targets; however, the
generation of effective reagents to a given target site is not guaranteed. ZFP engineering entails
significant design redundancy, with recent developments allowing targeting depths of N100
pairs for a given 25-bp sequence [45] and near-complete modification of target loci with unde-
tectable off-target activity in nuclear DNA [65]. By contrast, the engineering of TALE:DNA bindingTrends in Molecular Medicine, Month 2020, Vol. xx, No. xx 9
Outstanding Questions
What are the long-term effects of
mitochondrially targeted nuclease
treatments?
Is there potential to engineer DNA
protein binding motifs with reduced
catalytic rate while maintaining high
specificity?
Are some tissues, indications, or
modes of delivery better suited to
treatment with mitochondrially targeted
nucleases?
Are incomplete or heterogeneous
shifts of heteroplasmy across organs
sufficient to rescue clinical phenotypes?
Trends in Molecular Medicinespecificity is of far more limited scope, with significant preference for particular lengths of target
site and DNA sequence composition [52]. Although this may sometimes be advantageous
(e.g., T0 strategy), it also represents a significant limitation, and it is likely that the collection of
effective mitoTALENs will be less extensive than that of mtZFNs.
Efficient AAV Packaging and Dosage
Developing the capability for the delivery of either mtZFNs or mitoTALENs by AAV at safe
levels, compatible with current recombinant AAV manufacturing capacity and clinical guide-
lines, remains a major challenge [66]. The tactics employed in preclinical experiments thus
far are unlikely to be of broader use, as the delivery of significant amounts of two separate
AAVs into mice was required to detect heteroplasmy shifting activity by either programmable
nuclease platform [61,62]. If scaled to human dosage, these quantities of AAV would be
impractically high and potentially unsafe. Thus, methods that allow a reduction in the adminis-
tered titres of mitochondrial nuclease-encoding AAV will be key to clinical application.
Improved AAV capsid specificity, temporary immunosuppression regimens, focal injection/de-
livery into the organ of interest, and/or packaging of mtZFN or mitoTALEN monomers in a sin-
gle AAV capsid are potential ways in which this issue could be addressed. The clinical
development of programmable mitochondrial nucleases will be likely to hinge on advances
in these areas.
Concluding Remarks
Numerous approaches to shifting mtDNA heteroplasmy have been developed in parallel over the
past few decades. During this time, nuclease-mediated heteroplasmy shifting in particular has
matured from humble beginnings to robust technical platforms capable of efficiently shifting
various mtDNA heteroplasmies at will, both in vitro and in vivo [53,61,62] (see Table 2).Table 2. mtDNA Sequences and Models Successfully Targeted with Engineered Mitochondrial Nucleasesa
Genotype Gene Phenotype Model/tissue Method Refs
Human
m.3243ANG MT-TL1 MELAS iPSC mitoTALEN [55,56]
m.8344ANG MT-TK MERRF Cybrid mitoTev – TALE [58]
m.8483_13459del4977 Multiple CPEO,
KSS,
Pearson
Cybrid mtZFN, mitoTALEN [21,22]
m.8993TNG MT-ATP6 NARP,
Leigh
Cybrid mtZFN [21,50]
m.9176TNC MT-ATP6 NARP Murine oocyte/
cybrid fusion
mitoTALEN [53]
m.13513GNA MT-ND5 MELAS,
Leigh
iPSC mitoTALEN [54,56]
m.14459GNA MT-ND6 LHON Cybrid mitoTALEN [22]
Mouse
m.5024CNT MT-TA CM Heart, skeletal muscles mtZFN/mitoTALEN [61,62]
BALB/NZB – – Skeletal muscles, brain,
embryo, oocyte
(mitoTALEN)
mitoRE/mitoTALEN [36,53]
aAbbreviations: CM, cardiomyopathy; CPEO, chronic external ophthalmoplegia; Leigh, Leigh syndrome; LHON, Leber’s
hereditary optic neuropathy; MELAS, mitochondrial encephalomyopathy lactic acidosis with stroke-like episodes; MERRF
myoclonic epilepsy with ragged red fibres; NARP, neuropathy, ataxia, retinitis pigementosa; Pearson, Pearson marrow–pan-
creas syndrome.
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Trends in Molecular MedicineWhile the clinical potential of mitochondrially targeted programmable nucleases is clear, the
means of transition to clinical use requires further work. Although the application of these nucle-
ases for somatic manipulation of heteroplasmy in patients with mitochondrial disease appears
likely, they could similarly be used to eliminate carryover of mutant mtDNA, a potential complica-
tion of mitochondrial donation/mitochondrial replacement therapy [5]. Beyond the realms of
mitochondrial disease, the mtDNA heteroplasmy of human cancers is also likely to represent a
meaningful therapeutic target [2]. However, as potential first-in-class gene therapy approaches,
these methods currently face an uncertain regulatory environment in addition to the requirement
for necessarily robust preclinical evaluation and assessment.
Obvious challenges and strategic considerations notwithstanding (see Outstanding Questions),
the creation of powerful genetic tools, such as mtZFNs and mitoTALENs, has fired the starting
gun in the race for heteroplasmic mitochondrial disease gene therapy. The era of mitochondrial
genome medicine, while certainly still on the horizon, has never been closer.
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